March 24, 2021 -- Artificial intelligence (AI) drug discovery software developer Model Medicines has signed a deal with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.
The collaboration leverages Model Medicines' ActivPred AI drug discovery platform with Sanford Burnham Prebys' identification of novel antiviral targets and scientific expertise to discover and develop new treatments for SARS-CoV-2 and other infectious diseases. The digital chemistry drug development platform identifies novel biological targets that cannot be resolved with traditional high-throughput screening approaches.
Financial details of the collaboration were not disclosed.
Copyright © 2021 scienceboard.net